Bioinformatics

DiHeSys-Digital Health Systems is a start-up company located in Ulm, Germany and delivers solutions to transform digital information into personalized medication. The company comprises IoT platform systems combined with individualized healthcare solutions, e.g. 2D & 3D drug printing as well as e-health applications. Customers are in the field of big pharma, hospitals, health insurances & pharmacies. DiHeSys delivers customized integrated healthcare systems including patient demand-based manufacturing solutions as well as functional healthcare systems in structural-low areas.

IDTechEx identifies top future technologies in healthcare. With demographic changes such as the aging of the population, they forecast there to be strong growth in technologies that help healthcare providers manage the growing burden on the healthcare system while maintaining high quality care.

The current outbreak of a novel coronavirus (2019-nCoV) has hit China in the past month and spread to 25 nations. Early detection and diagnosis are essential to reduce the prevalence of infectious diseases and to prevent them from becoming epidemic or even pandemic.

A thin image sensor that allows for both high-speed readout and high-resolution imaging.

This trial is one of a new breed of clinical trials which showcase the potential of patient-centered research, taking advantage of portable and comfortable medical-grade wearables and innovative big-data platforms.

Medical imaging is essential for diagnosing and monitoring numerous cardiovascular conditions. While they have been of tremendous value in the past, traditional cardiovascular imaging methods are no longer meeting the requirements of patients and physicians. They can be difficult to interpret and lengthy to process, which delays time to treatment. New methods are needed to keep up with demand and provide a higher standard of care.

Researchers are conducting a clinical trial to evaluate the efficacy of bioelectronic medicine to treat pain associated with lupus, a chronic and potentially fatal autoimmune disease affecting upwards of 5 million people around the world.

Researchers used cryptography to cloak irrelevant genetic information in individuals' genomes while revealing disease-associated mutations. They say the technique could vastly improve patient privacy.

Researchers have discovered how Cas1-Cas2, the proteins responsible for the ability of the CRISPR immune system in bacteria to adapt to new viral infections, identify the site in the genome where they insert viral DNA so they can recognize it later and mount an attack.